Get started
Work

CTC-based biomarkers & PSMA-targeted imaging in patients with metastatic castrate-resistant prostate cancer (mCRPC)

Year: 2018
Type: article
Abstract: Background: Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancers, making it an imaging & therapeutic target of interest. The utility of the PSMA-targeted imaging agent 99mTc-EC0652 is being evaluated, along with biomarker analysis of circulating tumor cells (CTCs), in pts with mCRPC in a completed PSMA-targeted chemotherapeutic study. We now report the PSMA heterogeneity via CTC vs. imaging in the pt population treated to date.
DOI: 10.1093/annonc/mdy284.051
Authors: M.J. Morris, N.J. Vogelzang, O. Sartor, A. Armour, R. Messmann, M. Groaning, A. Robarts, A.W. Tolcher, M. Gordon, H.M. Babiker, P. Kuo, M. Kearney, A. Jendrisak, Y. Wang, M. Landers, D.P. Petrylak
Institutions: Memorial Sloan Kettering Cancer Center, Comprehensive Cancer Centers of Nevada, Tulane University, Endocyte (United States), HonorHealth, University of Arizona Cancer Center, Epic Sciences (United States), Yale University
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W2898462860
FWCI:
Cites:
Cited by:
Related to: 10